Navigation Links
Johnson & Johnson Announces Sale of Elan American Depositary Shares to Elan
Date:4/18/2013

not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; significant adverse litigation or government action; impact of business combinations; financial distress and bankruptcies experienced by significant customers and suppliers; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; increased scrutiny of the health care industry by government agencies; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and sovereign risk; disruptions due to natural disasters; manufacturing difficulties or delays; complex global supply chains with increasing regulatory requirements; and product efficacy or safety concerns resulting in product recalls or regulatory action. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended December 30, 2012.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)


'/>"/>
SOURCE Johnson & Johnson
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Johnson Electric Launches Medication Dosing Systems
2. Johnson & Johnson to Host Analyst Conference Call on First-Quarter Results
3. Johnson & Johnson gibt Eröffnung des Innovationszentrums in London bekannt
4. Johnson & Johnson Announces Opening of London Innovation Centre
5. Kevin Johnson Joins United Allergy Services Board Of Directors
6. Free Research Report on Delta Air Lines, Inc., Johnson & Johnson, Barrick Gold Corp., Exelon Corp. and Cirrus Logic, Inc.
7. Huntington Memorial Hospital Elects Paul Johnson, Deborah Williams to its Board of Directors
8. Johnson & Johnson Presents Growth Strategies for Medical Devices & Diagnostics Segment
9. Alliqua Names David Johnson Executive Chairman of Aquamed Technologies and Member of Alliqua Board of Directors
10. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
11. Johnson & Johnson Postpones Medical Devices & Diagnostics Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... MINNEAPOLIS , July 23, 2014 ... they have added 14 new vendors so far ... Creekridge,s newest vendors are from both ... mid-size domestic organizations to large, well-known multi-national companies. ... Creekridge,s diversified suite of financing products including: standard ...
(Date:7/23/2014)... , July 23, 2014  Mezzion Pharma Co. ... to evaluate the use of udenafil to treat adolescents ... ventricle heart defects. The clinical program will follow protocols ... the Pediatric Heart Network (PHN), a multi-center clinical research ... Institute (NHLBI) of the National Institutes of Health (NIH). ...
(Date:7/23/2014)... , July 23, 2014  Lightlake Therapeutics ... addiction treatments based on its expertise in opioid ... investigational new drug application ("IND") with respect to ... also announced today that it has received an ... Abuse ("NIDA"), part of the National Institutes of ...
Breaking Medicine Technology:Creekridge Capital Signs Several New Vendor Partners 2Mezzion Pharma Initiates Clinical Development Program To Evaluate Udenafil In Adolescents With Single Ventricle Heart Defects 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3
... Orthopedic Group, Inc. (NYSE: HGR ) announced that it continues ... Prosthetics of Texas , Nebraska Orthotic and Prosthetic Services, and Spectrum ... with annual revenues of $14.0 million . , ... "These companies are leaders in their communities ...
... June 22 Draeger Medical Canada, Inc. today announced ... System (AIMS) for the Capital District Health Authority and IWK Health Centre ... , , ... of the most comprehensive information technology solution for the safe delivery and ...
Cached Medicine Technology:Hanger Orthopedic Group, Inc. Announces Three Acquisitions With Annual Revenues of $14.0 Million 2Capital District Health Authority and IWK Health Centre to Implement Anesthesia Information Management System 2Capital District Health Authority and IWK Health Centre to Implement Anesthesia Information Management System 3
(Date:7/23/2014)... 23, 2014 Four hospitals affiliated with ... in the latest ranking of the country’s best hospitals ... Released online today and slated for publication in August, ... General Hospital (AGH), Forbes Hospital, Saint Vincent Hospital and ... multiple clinical specialties. , “There is no ...
(Date:7/23/2014)... WEDNESDAY, July 23, 2014 (HealthDay News) --,Jealousy may not ... showing dogs can get downright possessive when it comes ... owners showed affection toward what was actually a stuffed ... snapping or pushing the stuffed dog aside, report researchers ... This jealous streak only surfaced when owners were attending ...
(Date:7/23/2014)... In a massive effort to catalog the ... at Dana-Farber Cancer Institute, have identified four subtypes ... molecular abnormalities. They say the new classification promises ... for the third-leading cancer killer worldwide. , In ... The Cancer Genome Atlas Research Network said they ...
(Date:7/23/2014)... Texas Physical Therapy Specialists (TexPTS) is ... Westlake, Westgate, Liberty Hill, Parmer, Balcones, and Georgetown clinics ... Orthopaedic Certified Specialist (OCS) or Sports ... DPT, OCS, Tony Lauretta, PT, DPT, OCS, Jason Brown, ... Leech, PT, DPT, OCS, and Mary Grimberg, PT, DPT, ...
(Date:7/23/2014)... 2014 A therapy combining salmon fibrin injections into ... into the brain restored voluntary motor function impaired by ... Center have found. , In a study on rodents, ... turning back the developmental clock in a molecular pathway ... and providing a scaffold so that neuronal axons at ...
Breaking Medicine News(10 mins):Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 2Health News:Four Allegheny Health Network Hospitals Named High Performers by U.S. News 3Health News:Dogs Can Get Jealous, Too 2Health News:New view of stomach cancer could hasten better therapies 2Health News:New view of stomach cancer could hasten better therapies 3Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 2Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 3Health News:Gene inhibitor, salmon fibrin restore function lost in spinal cord injury 2
... cancer tumours change their hormonal status throughout the course ... treatment for the patient is usually only based on ... biopsy verifications of any relapse will be very important ... Swedish researcher will tell the 2011 European Multidisciplinary Cancer ...
... develop bone metastases, and controlling the pain these cause ... III trial of a bisphosphonate drug in these patients ... is as good for pain relief as single dose ... the trial were presented today (Sunday) at the 2011 ...
... firm evidence that giving radiotherapy between or during chemotherapy ... the risk of the cancer recurring in the breast ... has minimal adverse side-effects and no detrimental effect on ... the SEquencing of Chemotherapy and Radiotherapy in Adjuvant Breast ...
... Melanoma of the eye (ocular or uveal melanoma) frequently spreads ... no effective treatment and patients die within an average of ... live for a year. Now, final results from a phase ... the time patients can live without the disease progressing. ...
... FRIDAY, Sept. 23 (HealthDay News) -- Primary care and ... a patient to another doctor, a new study finds. ... after clinical expertise, primary care doctors consider issues such ... to base their decisions on their other patients, experiences ...
... Researchers have identified five new genes that play a role ... -- the most common cause of premature death and disability ... The international consortium said their discovery could help scientists predict ... condition. In conducting the study, published online Sept. 22 ...
Cached Medicine News:Health News:Breast cancer tumor make-up changes through the course of disease 2Health News:Breast cancer tumor make-up changes through the course of disease 3Health News:Bone-strengthening drug gives pain relief in prostate cancer bone metastases 2Health News:Bone-strengthening drug gives pain relief in prostate cancer bone metastases 3Health News:Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence 2Health News:Radiotherapy between or during chemotherapy cycles reduces risk of breast cancer recurrence 3Health News:Infusing chemotherapy into the liver gives extra months of disease-free life in melanoma patients 2Health News:Infusing chemotherapy into the liver gives extra months of disease-free life in melanoma patients 3Health News:Infusing chemotherapy into the liver gives extra months of disease-free life in melanoma patients 4Health News:Scientists ID More Genes Linked to Heart Disease 2
... achieves a secure clot, targeted to the ... hemostasis is needed, when control of bleeding ... and cautery, is ineffective or impractical., CROSSEAL* ... of human Biologically Active Component (BAC) and ...
Mastisol Liquid Adhesive is a clear, non-irritating, and non-water-soluble liquid adhesive that secures the most difficult dressings for an extended period of time. Mastisol is 7 to 10 times stickier...
... Indermil® tissue adhesive is indicated for ... laparoscopic incisions, and trauma-induced lacerations in areas ... thoroughly-cleansed, and have easily approximated skin edges. ... tissue adhesive may act as a barrier ...
The first Ethyl-2-Cyanoacrylate tissue adhesive in a tube that is more economical than sutures!...
Medicine Products: